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Abstract: 
Objective: The main purpose of the study is to determine the survival and death rate of the female after surgical operation. This is 
determined by the two different methods of treatment between the females suffering from ovarian cancer.  
Methods: The study arranged was of a retroactive type and it was held at Mayo Hospital, Lahore from February to September 
2017. The study was associated with the data obtained in 1999 and 2008 about the female’s treatment suffering from ovarian 
cancer. The clinical data obtained during the previous analysis was again studied and revised. And similar knowledge was obtained 
about the environmental, medical, therapeutically, pathological aspects of studies. Overall existence of patients was compared 
with growthfree existence. The comparison was made between patients who went either debulking surgery or neoadjuvant 
chemotherapy before surgery. Mathematical identification was performed by using SPSS.   
Results: Total 118 patients were undergone surgical cure. Out of which 66% gained the primary debulking surgery and rest of the 
34% received neoadjuvant chemotherapy. The average age and tumour antigen 125 level before treatment was same. In the 
debulking group, two stages of patients were identified. That group had 94.8% patients with stage 3 carcinoma and 5.1% stage 4 
carcinoma. While in other groups the percentage of patients in stage 3 and 4 were 80% and 20% correspondingly. The most 
favourable occurrence of debulking was 56.8% in the earlier group as compared to 79.4% in the second group. At the time of 
surgery, the total loss of blood was recorded as 1500 ml. The loss of blood was almost the same in the different exhaustive care 
unit. In addition to the loss of blood, the rate of urinary swathe, bowel grievance and bowel reactions were also analogous. The 
growth free existence was also comparable in both groups.   
Conclusion: Equivalent existence rates and peri-operative difficulties can be created by neo-adjuvant chemotherapy followed by 
intermission debulking.  
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INTRODUCTION: 
An ovarian tumour is a disorder mainly present in 
females. Its early identification is difficult because it 
shows very light and distracted cypher in the early 
phase. The other cause of its prevalence and severity 
is that there is no special test or device for its early 
identification [1, 2].  
It's starts showing it some symbols when it has 
prevailed to the upper part of the belly and outlying 
regions [3]. It was observed that disease reached to 
about 70% of its prevalence when it shows symptoms 
in case of stage-III and stage-IV. At this stage, only a 
10% chance of survival of patients exists. The chances 
of survival can be enhanced if the disease can be 
identified at the early phase of growth. Chances could 
be improved to about 80-90% by early diagnosis [2, 
3].   
Recently, the most applicable cure for ovarian cancer 
which shows the best results is primary debulking 
surgery followed by chemotherapy. In debulking 
surgery overall hysterectomy of the belly with two-
sided sapling-oophorectomy, inclusive omentectomy 
and resection of any metastatic disorder are performed. 
Recovery of the patient depends on the capabilities of 
the medical doctor and level of disease. If the disease 
has been spread to the upper part of the belly and 
under-surface of the diaphragm than the optimal 
cytoreduction becomes complicated to perform. It has 
been found that the death rate increases due to such 
type of hindrance. But it has been explained by the 
observation of many studies that optimal 
cytoreduction is very significant future expecting 
factor for the livelihood of the patients [4 – 7].   
The second frequently used treatment for ovarian 
carcinoma is neo-adjuvant chemotherapy with 
surgery. This is the special surgical impend for the 
widespread disorder. Because of methodological 
complexity and patient’s medical death, entire 
therapeutical responses are not possible [8].   
NACT has been proved an important optimal 
cytoreduction because it lessened the burden of cancer 
prior to surgical treatment. It also reduces the death 
rates and quantity of blood loss in patients. So, it 
decreases the reside of patient in exhaustive care unit 
and hospitals [4, 9 – 12].  
Comparable conclusions were obtained when the 
European Organization for Research and Treatment of 
Cancer reports about the survival and growth-free 
survival compared between NACT and standard 
debulking surgery. The death rate was less in case of 
NACT group. So, it was considered that NACT can 
replace the debulking surgery [2, 13].  
The main objective of organizing this study was to 
compare the death rates of Pakistani females suffering 
from ovarian carcinoma in two groups. It is predicted 
that there is diversity in communal and financial 
aspects. Dietary status is also varying between the 
Pakistani and western patients. In this study, we 
compared the survival rate in females suffering from 
an ovarian tumour between primary debulking surgery 
and NACT followed by surgery and find out which 
treatment is more helpful.   
 
PATIENTS AND METHODS: 
The study arranged was of a retroactive type and it was 
held at Mayo Hospital, Lahore from February to 
September 2017. It was arranged after getting 
permission from institutional morals committee. The 
study included the data obtained between 1999 and 
2008 about the females with ovarian carcinoma. Other 
females like early-stage ovarian tumour or patients 
suffering from synchronous primaries, non-epithelial 
ovarian tumours and those females in which an ovarian 
tumour is repeated again and again were not added in 
the study.  
Females in both the groups were given the treatment 
with intravenous carboplatin and taxol-based 
chemotherapy. After 3 to 4 cycles of treatment, a 
notable changing observed in the patients for the 
capability of the therapy.   
The verdict to treat a patient with PDS or NACT was 
presented in front of the tumour board jury. This jury 
consisting of gynaecological oncologist and clinical 
oncologist. This decision was made keeping in view 
some factors such as World Health Organization 
functional status of the patients, remedial co 
melancholic and on the fact that if the disease was 
hindered at the time of appearance. To find out the 
respectability of the disease, a central line imaging was 
needed like computed tomography of the chest, belly 
and pelvis bone. We can describe the unresectable 
disease as profound penetration of small bowel 
mesentery; disperse carcinomatosis consisting of the 
stomach and minute or bulky bowel; penetration of 
duodenum or fraction of the pancreas; and 
contribution of the liver parenchyma.   
If TAH, BSO, omentectomy, hindrance of inflamed 
pelvic lymph knot and hindrance of implants were 
identified, standard debulking surgeries for both 
groups were recommended. Before starting the 
chemotherapy patients in the NACT group were 
investigated first. The investigation was established 
pathologically by tissue biopsies.   
Substantial assessment, carcinoma antigen-125 
amount and CT imaging were done repeatedly to 
recognize the reactions of the patients on various 
treatment methods after a regular period of time.   
We can characterize the finest cytoreduction as no 
lasting disease or less than the 1cm lasting disease in 
maximal measurement at the last of therapy. The 
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disease can be divided by using the Intercontinental 
Federation of Gynecologists and Obstetrician 
dramatization scheme [15]. All type of environmental, 
medical, therapeutically, pathological and summarize 
knowledge was gained by revising all the clinical data 
and proceedings of the patients. Two groups of 
handling competed with each other between 
growthfree existence and overall existence. Some 
other parameters between these two groups also 
competed with each other. These included endurance 
rates before surgery, expected loss of blood, concern 
given to the victim during the surgical difficulties 
faced by patients such as bladder and bowel damage 
and complexities faced by patients after surgery like 
infections and thromboembolism.  
Information was analyzed and recorded by using the 
SPSS. Chi-square analysis was used for comparing 
definite variables. Kaplan Meier Survival curves were 
used to engender the existence chances of the patients. 
In evocative information, to measure uninterrupted 
usually dispersed numbers averages and standard 
deviations were used. While non-normal allocation 
can be considered by median and range. For definite 
numbers, regularity and ratios were analyzed. 
Relationship of medical and pathological 
distinctiveness can be identified by either Pearson’s 
chi-square test or Fisher exact test. Product-limit 
estimates were used to measure all median and life 
tables. Long-rank test was used to analyze curves. The 
mathematically important value was measured as P< 
0.05.  
 
RESULTS: 
Total 118 patients with ovarian carcinoma were 
selected. Out of these 66% received PDS and 34% 
were undergone treatment by NACT method.  
The average age and CA-125 level before surgery were 
almost the same. 94.8% of patients belong to stage 3 
and 5.1% to stage 4, in the case of debulking groups. 
While if we talk about the other groups 80% patients 
belongs to stage 3 and rest of the 20% belongs to stage 
4 diseases. The average figure of neo-adjuvant cycles 
was 6. The papillary serous tumour was the most 
abundantly found carcinoma. It was present 72.7% in 
PDS groups and 89.7% in NACT group.   
The time required for surgery expected the flow of 
blood during surgery which was about 1500ml and 
presence of a patient in the exhaustive care unit was 
also similar in different studies. The rate of urinary 
swathe, bowel grievance, and bowel responses was 
also comparable. Growth-free existence was also 
comparable in both the groups. The frequency of 
optimal debulking was slightly different in the two 
groups. It was calculated to be 56.8% in the earlier 
group and 79.4% in the second group.  
Median existence result was calculated to be 30 
months in NACT and 32 months in oDS group. In the 
same way, growth-free existence in two groups was 
also comparable.  
  
Table – I: Overall PDS Versus NACT 
  
PDS/NACT  Number  Percentage  
PDS  78  66  
NACT  40  34  
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Table – II: Stage and History Features (PDS Versus NACT) 
  
Characteristics (%)  PDS (78)  NACT (40)  
Stage  
Stage – III  94.8  80.0  
Stage – IV  5.1  20.0  
History  
Serous  72.7  89.7  
Mucinous  6.1  3.4  
Endometroid  16.7  6.9  
Clear Cell  3.0  0.0  
  
  
 
  
Table – III: Average Values (PDS Versus NACT) 
 
Average Values  PDS (78)  NACT (40)  
Mean  ±SD  Mean  ±SD  
Age  50.99  13  52.45  11.3  
Ca-125  1954  2762.4  1909  2486.4  
Surgical Time  222  185.3  222  196.6  
Blood Loss  848  467.5  874  517.3  
Hospitalization  2.5  2.16  2.89  3.7  
  
  
  
Stage - III 
Stage - IV 
Serous 
Mucinous 
Endometroid 
Clear Cell 
NACT (40) PDS (78) Poly. (PDS (78)) Log. (NACT (40)) 
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Table – IV: PDS Versus NACT (Various Features) 
  
Characteristics  PDS (78)  NACT (40)  
Blood Loss (Above 1500 ml)  13.5  13.5  
Bowel Resection  15  12  
Urinary Tract Infection  3.12  0.4  
Optimal Debulking  56.8  79.4  
  
  
 
  
PDS: Primary debulking surgery  
NACT: Neo-adjuvant chemotherapy  
  
MEAN ± SD MEAN ± SD 
PDS (78) NACT (40) 
Age Ca-125 Surgical Time 
Blood Loss Hospitalization Poly. (Ca-125) 
Poly. (Blood Loss) 
  
1 3.5 
5 1 
3.12 
56.8 
1 3.5 
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79.4 
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DISCUSSION:  
Overall cytoreduction of carcinoma is the major 
purpose of the surgery of epithelial ovarian tumour. 
The strength of remaining disease after cytoreduction 
was negatively related to the existence of patients 
which was inveterate by meta-analysis of about 6000 
victims of the disease [5, 6, 16]. It is a common 
perception that suboptimal cytoreduction does not give 
any survival facilities to the females who are suffering 
from sophisticated stages of carcinoma. So optimal 
cytoreduction should be used for better results. The 
optimal cytoreduction depends mainly on the abilities 
and skills of the doctors but still, it is affordable 
because it increases the chances of survival [17, 18].  
The Gynecologic Oncology Group describes the most 
favourable cytoreduction as parting utmost of 1cm 
remaining disease. While on another hand whole 
cytoreduction means total clearance of remaining 
disease. It may involve more intense and aggressive 
surgical methods. So, it may cause the additional flow 
of blood during surgery, more time required for 
surgery and quantity of blood transfused [19].   
debulking surgery followed by chemotherapy is 
considered to be the better treatment for ovarian 
carcinoma from the previous 30 years. But now 
different other methods gained popularity; Different 
surgical methods have been used now a day for the 
patients who are not well medically or those whose 
disease has been spread to a large extent. After 
completion of three to six cycles of NACT debulking 
surgery is performed in these victims. To compare the 
primary debulking followed by chemotherapy and 
NACT followed by debulking many observations were 
made. Chemotherapy and EORTC also competed with 
these two treatment methods. They also show similar 
chances of survival in both groups. It was concluded 
that the morbidity rate is less in NACT patients 
followed by debulking surgery [2, 13].  
An association was also observed between NACT and 
longer existence rate according to the reports of some 
studies [20, 21]. Demographic history was the same 
according to our observations in both groups. Intra-
operative and post-operative parameters were also 
similar in both groups according to our study. It has 
been identified that blood loss and residence in ICU is 
also the same in both cases. Previous studies also show 
comparable results [4, 21, 22].  
In our observations, the major cytoreduction rate for 
PDS was 56.8% and 79.4% for NACT. These results 
were important and similar to other studies [9, 23]. The 
pre-operative CA-125 rate was comparable in our 
study although there exists a variation in optimal 
cytoreduction. No comparison between the existence 
rates was identified in our study. Operation of the 
upper part of the belly is difficult to perform in our 
study which is also a weak point of our study.  
 
CONCLUSION:  
Similar existence rates and complexities before the 
operation, most favourable debulking was obtained by 
NACT followed by intermission debulking. It can be 
conveniently supposed in a group of patients having 
poor workings, clinical comorbidities and unhindered 
disease at the time of appearance.  
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